ResultsIQ

ResultsIQ › Latest results › Wockhardt Limited

Wockhardt Limited investor meet summary

NSE: WOCKPHARMA · BSE: 532300

Investor meet of 4 Jun 2026, summarised by AI from the filing.

Wockhardt guides Zaynich global peak sales of $1.5-2 billion and expects breakeven in 12-18 months after US FDA approval.

Key takeaways

  1. US FDA approval Zaynich approved by US FDA, first Indian research product approved; CDSCO India approval also received.
  2. Growth driver Zaynich launch in US and India, biosimilar expansion, and emerging market partnerships drive growth.
  3. Execution risk Building new commercial organization for Zaynich is biggest challenge over next 12-18 months.

Original filing on BSE

Wockhardt Limited Q1 FY27 results

As filed: Revenue ₹929 cr (+26% year on year), EBITDA ₹192 cr (+167% year on year), PAT ₹107 cr, EBITDA margin 20.7% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹965 cr (+30% year on year), EBITDA ₹225 cr (+252% year on year), PAT ₹164 cr, EBITDA margin 23.3% (+1,000 bps). Score 78 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate 13%. Share price after the results: +45.5% in 30 days (Nifty 500: −1.7%).
  • Q3 FY26: Revenue ₹888 cr (+23% year on year), EBITDA ₹177 cr (+38% year on year), PAT ₹61.0 cr (+267% year on year), EBITDA margin 19.9% (+218 bps). Score 59 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 218 bps year on year. Other income 37% of PBT. Tax rate 9%. Profit fell 15% from last quarter. Share price after the results: −8.0% in 30 days (Nifty 500: −7.5%).
  • Q2 FY26: Revenue ₹782 cr (−3% year on year), EBITDA ₹178 cr (+62% year on year), PAT ₹82.0 cr, EBITDA margin 22.8% (+917 bps). Score 45 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 917 bps year on year. Tax rate 10%. Share price after the results: +10.4% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹738 cr (0% year on year), EBITDA ₹72.0 cr (−21% year on year), PAT −₹108 cr, EBITDA margin 9.8% (−256 bps). Score 15 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 256 bps year on year. Share price after the results: −2.8% in 28 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹743 cr (+6% year on year), EBITDA ₹64.0 cr, PAT −₹45.0 cr, EBITDA margin 8.6% (+1,000 bps). Score 45 of 100, In line with trend. Revenue growth was in line with the company's own trend. EBITDA margin rose 1000 bps year on year. Profit fell 325% from last quarter. Share price after the results: +22.7% in 29 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹721 cr (+3% year on year), EBITDA ₹128 cr (+246% year on year), PAT ₹20.0 cr, EBITDA margin 17.8% (+1,000 bps). Score 44 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was above it. EBITDA margin rose 1000 bps year on year. Other income 38% of PBT. Tax rate 5%. Revenue fell 11% from last quarter.
  • Q2 FY25: Revenue ₹809 cr (+7% year on year), EBITDA ₹110 cr (+53% year on year), PAT −₹16.0 cr, EBITDA margin 13.6% (+404 bps). Score 45 of 100, In line with trend. EBITDA margin rose 404 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Wockhardt Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.